The Tough Tech problem we are solving
The Covid-19 pandemic highlighted the need for increased biomanufacturing capacity and risk-free scalability worldwide. From American biodefense infrastructure to the commercial development and production of mAbs, bio-manufactured therapeutic pipelines will only increase in prevalence, constituting a trillion dollar market yearly. However, there are major bottlenecks in the process that have seen little to no advancement in decades, leading many to believe they are “unavoidable.”
About our solution
At Evoworks Bio, we believe the lengthy process development, high capex, and inherent risks of manufacturing a new therapeutic at scale are the result of a lack of technological innovation. Our proprietary platform obsoletes the majority of the current workflow, removing scalability risk, reducing time-to-market by 1-2 years, and lowering costs by as much as 10x. The resolution of these key problems will open the gate for hundreds of new therapeutics each year, allowing developers to quickly and easily reach animal testing, clinical trials, and even full manufacturing all without worrying about the “scalability” of their solutions.